Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $285.70, for a total transaction of $3,142,700.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at approximately $10,508,331.70. This represents a 23.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Stock Up 0.1%

Shares of UTHR stock traded up $0.18 during mid-day trading on Friday, reaching $284.27. The company's stock had a trading volume of 462,926 shares, compared to its average volume of 447,589. The company's 50 day simple moving average is $301.13 and its 200-day simple moving average is $325.65. The firm has a market capitalization of $12.82 billion, a PE ratio of 11.34, a price-to-earnings-growth ratio of 6.26 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.17 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on UTHR. Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Morgan Stanley increased their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Cantor Fitzgerald started coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective for the company. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $393.08.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. SVB Wealth LLC bought a new position in United Therapeutics in the 1st quarter worth approximately $32,000. Dunhill Financial LLC lifted its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. Sound Income Strategies LLC purchased a new stake in shares of United Therapeutics in the first quarter worth approximately $49,000. Finally, Brooklyn Investment Group increased its stake in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 98 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.